In association with the lower PD-L1 expression, this possibly contributes to the absence of an immune response that confers a poorer prognosis and a potential resistance to immunotherapy for this subset of HNSCC patients. The gene discussed is CD274; the disease is head and neck squamous cell carcinoma.